Abstract
Mortality due to colorectal cancer (CRC) is high and is associated with the development of liver metastases. Approximately 40% of human CRCs harbor an activating mutation in the KRAS oncogene. Tumor cells with activated KRAS are particularly sensitive to Reovirus T3D, a non-pathogenic oncolytic virus. The efficacy of virus-based therapies may be positively or negatively modulated by the host immune system. This study was designed to assess the effect of immunosuppression on Reovirus T3D oncolysis of established colorectal micrometastases in the liver. Mouse C26 CRC cells harbor a mutant Kras gene and are susceptible to Kras-dependent oncolysis by Reovirus T3D in vitro. Isolated C26 liver tumors were established in syngenic immunocompetent BALB/c mice by intrahepatic injection. Reovirus T3D therapy was given as a single intratumoral injection in control mice and in cyclosporin A-treated immunosuppressed mice. Tumor growth was analyzed over time by non-invasive bioluminescence imaging. The outgrowth of established CRC liver metastases in immunocompetent mice was efficiently but temporarily inhibited with a single injection of Reovirus T3D. Immunosuppression with cyclosporin A markedly increased and prolonged the therapeutic effect and allowed complete Reovirus T3D-induced tumor eradication in a subpopulation of the mice. We conclude that Reovirus T3D is an effective therapeutic agent against established C26 colorectal liver metastases and that immunosuppression enhances treatment efficacy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Everts B, van der Poel HG . Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12: 141–161.
Forrest JC, Dermody TS . Reovirus receptors and pathogenesis. J Virol 2003; 77: 9109–9115.
Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332–1334.
Smakman N, van den Wollenberg JM, Borel Rinkes IHM, Hoeben RC, Kranenburg O . Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 2005; 79: 14981–14985.
Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA . Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. J Natl Cancer Inst 1998; 90: 675–684.
Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 2004; 10: 8561–8576.
Norman KL, Lee PW . Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005; 10: 847–855.
Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348–353.
Smakman N, Martens A, Kranenburg O, Borel Rinkes IH . Validation of bioluminescence imaging of colorectal liver metastases in the mouse. J Surg Res 2004; 122: 225–230.
Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM, Demetrick DJ . Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (Dearing 3) as an anti-cancer biotherapeutic. Cancer Biol Ther 2004; 3: 734–738.
Acknowledgements
We thank A Verheem for excellent technical assistance. NS was financially supported by the Wijnand M Pon foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Smakman, N., van der Bilt, J., van den Wollenberg, D. et al. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 13, 815–818 (2006). https://doi.org/10.1038/sj.cgt.7700949
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700949
This article is cited by
-
The oncolytic virus, pelareorep, as a novel anticancer agent: a review
Investigational New Drugs (2015)
-
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
Cell Death & Disease (2013)
-
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
Oncogene (2012)
-
Immunosuppression Enhances Oncolytic Adenovirus Replication and Antitumor Efficacy in the Syrian Hamster Model
Molecular Therapy (2008)
-
Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles
Cancer Gene Therapy (2008)